eFFECTOR Therapeutics Raises $38.6M

San Diego-based eFFECTOR Therapeutics, a developer of treatments for cancer, has raised $38.6M in a Series C funding round, the company announced this morning. The funding was led by Pfizer Venture Investments (PVI), and also included Alexandria Venture Investments, along with U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, and Astellas Ventures. Pfizer's Elaine V. Jones joins eFFECTOR's board with the new funding round. eFFECTOR said the funding goes towards Phase 2 efforts for eFT508, the company's investigational small molecule MNK1/2 inhibitor, which is currently being studied for treating colerectal cancer. eFFECTOR Therapeutics has now raised $139.6M in total funding. More information »